<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00718289</url>
  </required_header>
  <id_info>
    <org_study_id>012008</org_study_id>
    <nct_id>NCT00718289</nct_id>
  </id_info>
  <brief_title>Citrate- Versus Acetate-Based Dialysate in Bicarbonate Haemodialysis: Consequences on Haemodynamics, Coagulation, Acid-Base Status and Electrolytes</brief_title>
  <official_title>Citrate- Versus Acetate-Based Dialysate in Bicarbonate Haemodialysis: Consequences on Haemodynamics, Coagulation, Acid-Base Status and Electrolytes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale Regionale di Locarno</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bichsel AG, Interlaken, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ospedale Regionale di Locarno</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      A concentrate for bicarbonate haemodialysis acidified with citrate instead of acetate has&#xD;
      been marketed in the recent years. The small amount of citrate used (one-fifth of the&#xD;
      concentration adopted in regional anticoagulation) protects against intradialyser clotting,&#xD;
      minimally affecting the calcium concentration. The aim of this study is to compare the impact&#xD;
      of a citrate- and acetate-based dialysate on systemic haemodynamics, coagulation, acid-base&#xD;
      status, calcium balance and dialysis efficiency.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      In 25 patients, 375 dialysis sessions, we will compare acetate (A) with citrate dialysate&#xD;
      with (C+) or without (C) calcium supplementation (0.25mmol/L) in a randomized single blind&#xD;
      cross-over study. Systemic haemodynamics will be evaluated using pulse wave analysis systems.&#xD;
      Coagulation, acid-base status, calcium balance and dialysis efficiency will be assessed using&#xD;
      standard biochemical markers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction:&#xD;
&#xD;
      A concentrate for bicarbonate haemodialysis acidified with citric instead of the less&#xD;
      physiologic acetic acid has been successfully implemented in the United States in the past 7&#xD;
      years [1-3]. Contrarily to traditional regional citrate anticoagulation, the small amount of&#xD;
      citrate used in the acid concentrate (0.8 mmol/L only; about one-fifth of the concentration&#xD;
      necessary to achieve anticoagulation [1,4,5]) affects the calcium concentration and the&#xD;
      locally enhanced coagulation activation in a limited way, resulting in approximately 10%&#xD;
      reduction in post-dialysis ionized calcium and in no measurable systemic anticoagulation [1].&#xD;
      The absence of significant systemic repercussions is related to both, the low amount of&#xD;
      citrate used but also the rapid conversion of citrate into bicarbonate taking place in the&#xD;
      liver and muscles and determining a higher post-dialysis bicarbonataemia [1,6,7]. Despite the&#xD;
      rapid citrate clearance, the local consequences of removing calcium from the blood clotting&#xD;
      cascade has measurable positive effects on the dialyser life-span in the &quot;reuse&quot; modality and&#xD;
      on the dialysis quality quantified by urea Kt/V [1,3]. The improvement in urea clearance was&#xD;
      correlated to a postulated favourable effect on dialyser fibre permeability mediated by the&#xD;
      intra-dialyser anticoagulants properties of citrate [1,3,8]. Considering the importance of&#xD;
      limiting the biocompatibility related coagulation activation taking place in the&#xD;
      extracorporeal circuit [9-17], disposing of a simple way to inhibit it without affecting the&#xD;
      systemic coagulation and the bleeding risk [18] is very promising.&#xD;
&#xD;
      Even if thousands of patients have been treated in the recent years with haemodialysis fluids&#xD;
      based on citric instead of acetic acid, the haemodynamic tolerance (the reduction in ionized&#xD;
      calcium concentration and the increase in bicarbonateamia could both result in a lower&#xD;
      intra-dialytic blood pressure [19-25]) and the amount of systemic coagulation activation&#xD;
      related to each one of the modalities, were not investigated.&#xD;
&#xD;
      The aim of this randomized, controlled, single blind, cross-over study in single-use dialyser&#xD;
      bicarbonate haemodialysis, is to detail the consequences on systemic haemodynamics,&#xD;
      coagulation activation, acid-base status, calcium balance and dialysis efficiency of using&#xD;
      citric instead of acetic acid in the haemodialysis fluids.&#xD;
&#xD;
      Methods and patients:&#xD;
&#xD;
      Twenty-five chronic haemodialysis patients (15 male and 10 female), dialysed 3 to 4 hours&#xD;
      three times a week, clinically stable and without intercurrent illnesses, will be enrolled in&#xD;
      the study. Using a single blind, cross-over design, the patients will be randomized in the&#xD;
      two arms of the study beginning by either the traditional acetic acid (modality A) or the&#xD;
      citric acid dialysate (modality C). In the following 3 weeks the modality will be weekly&#xD;
      switched to the alternative one. Finally, with the intention to compensate the reduction in&#xD;
      serum calcium induced by the citrate binding, both study arms will be completed with a week&#xD;
      using a citric acid dialysate with a calcium supplementation of 0.25 mmol/L (modality C+).&#xD;
&#xD;
      The haemodialyses will be performed using a 4008 H machine, equipped with a cartridge of&#xD;
      bicarbonate Bibag©, and a high flux single use polysulfone membrane, all from Fresenius&#xD;
      Medical Care (Bad Homburg, Germany). The prescribed dialyser effective surface area, dialysis&#xD;
      fluid conductibility, temperature and composition (with the exception of acetate [3.0 mmol/L&#xD;
      in A and 0.3 in C and C+], citrate [0 mmol/L in A and 0.8 in C and C+] and calcium [1.25 and&#xD;
      1.50 mmol/L in A and C and 1.50 and 1.75 in C+]), and effective blood flow will be recorded&#xD;
      at the enrolment in the study, and left unchanged for the following 5 weeks. The medications&#xD;
      of the patients (including phosphate binders) will also be left unchanged.&#xD;
&#xD;
      Serum BUN, creatinine, potassium, phosphate, calcium and whole blood pH, bicarbonate, and&#xD;
      ionized calcium will be measured at the beginning and at the end of the third dialysis&#xD;
      session of each week. Ionized and total calcium will also be measured at the beginning and at&#xD;
      the end of the first dialysis session of each week. The prothrombin fragments 1+2 (F1+2) and&#xD;
      thrombin-antithrombin complexes (TAT) will be determined at the beginning and at the end of&#xD;
      the third dialysis session of each week [26]. Blood samples will be taken from the arterial&#xD;
      limb of the shunt.&#xD;
&#xD;
      Systolic and diastolic blood pressures and heart rate will be measured before starting every&#xD;
      session, and then repeated at 30 min interval throughout the dialysis with an automated Blood&#xD;
      Pressure Monitor 4008 (Fresenius Medical Care, Bad Homburg, Germany) integrated in the&#xD;
      dialysis machine. Stroke volumes (integrated mean of the flow waveform between the current&#xD;
      upstroke and the dicrotic notch) and peripheral resistances (ratio of mean arterial pressure&#xD;
      to stroke volume multiplied by heart rate) will be evaluated between 5 and 10 minutes after&#xD;
      starting the session and then every 45 minutes using a finger beat-to-beat monitor Finometer©&#xD;
      (Finapres Medical Systems BV, Arnhem, The Netherlands). The use of isotonic saline (100-200&#xD;
      ml) infusions to treat symptomatic hypotension or symptoms related to intravascular&#xD;
      hypovolaemia will be registered.&#xD;
&#xD;
      Kt/V will be calculated using a second generation single-pool Daugirdas formula (Kt/V =&#xD;
      -ln(R-0.03) + [(4-3.5 x R) x (UF/W)] where R = post-dialysis BUN/pre-dialysis BUN, UF = net&#xD;
      ultrafiltration and W = weight).&#xD;
&#xD;
      The citrate accumulation during dialysis will be estimated calculating the calcium gap =&#xD;
      │post-predialysis total calcium│- │post-predialysis ionized calcium│[6]. The value of 0.2&#xD;
      mmol/L will be used as a cut-off to divide the patients in rapid (&lt; 0.2 mmol/L) and slow (≥&#xD;
      0.2 mmol/L) metabolizers.&#xD;
&#xD;
      Results will be expressed as mean ± SD. Statistical analyses will be performed using a&#xD;
      statistical software package (SPSS 12.0; SPSS Inc., Chicago, IL, USA). Comparisons between&#xD;
      laboratory and haemodynamic parameters will be done first with an ANOVA followed if&#xD;
      significant by a paired t-test performed between the mean of the values obtained in each&#xD;
      patient with each modality. Haemodynamic parameters as a function of the dialysis time will&#xD;
      be compared using a trapezoidal estimation of the area under the curves followed by a&#xD;
      Wilcoxon Signed Ranks test. With the intention of ameliorating the understanding of the&#xD;
      haemodynamic changes, an evaluation of the maximum increase and decrease in each parameter&#xD;
      will be added to the data analysis (see Figure 2 for an explanation of the calculation&#xD;
      method). Percentages will be compared using a Fisher Exact test. In all cases, a P ≤ 0.05&#xD;
      will be considered statistically significant; P will be expressed as ns (not significant),&#xD;
      =0.05, &lt;0.05, &lt;0.01 and &lt;0.001.&#xD;
&#xD;
      The protocol of the study has been approved by the local Ethical Committee. All the patients&#xD;
      will give written informed consent prior to enrolment in the study.&#xD;
&#xD;
      References:&#xD;
&#xD;
        1. Ahmad S, Callan R Cole JJ, Blagg CR. Dialysate made from dry chemicals using citric acid&#xD;
           increases dialysis dose. Am J Kidney Dis. 2000;35,493-499.&#xD;
&#xD;
        2. Tu A, Ahmad S. (2000). Heparin-free hemodialysis with citrate-containing dialysate in&#xD;
           intensive care patients. Neph Dial Transplant. 2000;29,620-626.&#xD;
&#xD;
        3. Ahmad S, Callan R, Cole J, Blagg C. Increased dialyzer reuse with citrate dialysate.&#xD;
           Hemodial Int. 2005;9:264-267.&#xD;
&#xD;
        4. Apsner R, Buchmayer H,Gruber D, Sunder-Plassmann G. Citrate for long-term hemodialysis:&#xD;
           prospective study of 1,009 consecutive high-flux treatments in 59 patients. Am J Kidney&#xD;
           Dis. 2005;45:557-564.&#xD;
&#xD;
        5. Pinnick RV, Wiegmann TB, Diederich DA. Regional citrate anticoagulation for hemodialysis&#xD;
           in the patient at high risk for bleeding. N Engl J Med. 1983;308:258-61.&#xD;
&#xD;
        6. Bauer E, Derfler K, Joukhdar C, Druml W. Citrate kinetics in patients long-term&#xD;
           hemodialysis therapy.Am J Kidney Dis. 2005;46:903-907.&#xD;
&#xD;
        7. Gabutti L, Marone C, Colucci G, Duchini F, Schönholzer C. Citrate anticoagulation in&#xD;
           continuous venovenous hemodiafiltration: a metabolic challenge. Intensive Care Med.&#xD;
           2002;28,1419-1425.&#xD;
&#xD;
        8. Gabutti L, Colucci G, Martella A, Schönholzer C, Marone C. Does monitoring of&#xD;
           pre-/post-dialyzer pressure difference improve efficiency in intermittent hemodialysis ?&#xD;
           Blood Purif. 2003;21,294-300.&#xD;
&#xD;
        9. Gabutti L, Ferrari N, Mombelli G, Keller F, Marone C. The favorable effect of regional&#xD;
           citrate anticoagulation on interleukin-1beta release is dissociated from both&#xD;
           coagulation and complement activation. J Nephrol. 2004;17,819-825.&#xD;
&#xD;
       10. Stiekema JC. Heparin and its biocompatibility. Clin Nephrol. 1986;26:S3-8.&#xD;
&#xD;
       11. Cheung AK, Faezi-Jenkin B, Leypoldt JK. Effect of thrombosis on complement activation&#xD;
           and neutrophil degranulation during in vitro hemodialysis. J Am Soc Nephrol.&#xD;
           1994;5:110-115.&#xD;
&#xD;
       12. Böhler J, Schollmeyer P, Dressel B, Dobos G, Hörl W. Reduction of granulocyte activation&#xD;
           during hemodialysis with regional citrate anticoagulation: dissociation of complement&#xD;
           activation and neutropenia from neutrophil degranulation. J Am Soc Nephrol.&#xD;
           1996;7:234-241.&#xD;
&#xD;
       13. Hofbauer R, Moser D, Frass M, Oberbauer R, Kaye AD, Wagner O, Kapiotis S, Druml W.&#xD;
           Effect of anticoagulation on blood membrane interactions during hemodialysis. Kidney&#xD;
           Int. 1999;56:1578-1583.&#xD;
&#xD;
       14. Bos JC, Grooteman MP, Van Houte AJ, Schoorl M, Van Limbeek J, Nube MJ. Low&#xD;
           polymorphonuclear cell degranulation during citrate anticoagulation: a comparison&#xD;
           between citrate and heparin dialysis. Nephrol Dial Transplant. 1997;12:1387-1393.&#xD;
&#xD;
       15. Dhondt A, Vanholder R, Tielemans C, Glorieux G, Waterloos MA, De Smet R, Lameire N.&#xD;
           Effect of regional citrate anticoagulation on leukopenia, complement activation and&#xD;
           expression of leukocyte surface molecules during hemodialysis with unmodified cellulose&#xD;
           membranes. Nephron. 2000;85:334-342.&#xD;
&#xD;
       16. Bartels PC, Schoorl M, Wiering JG, Nube MJ. Activation of coagulation during treatment&#xD;
           with hemodialysis. Scand J Clin Lab Invest. 2000;60:283-290.&#xD;
&#xD;
       17. Wiegmann TB, McDougall ML, Diederich DA. Dialysis leukopenia, hypoxemia and&#xD;
           anaphylatoxin formation: effect of membrane, bath and citrate anticoagulation. Am J&#xD;
           Kidney Dis 1988;11:418-424.&#xD;
&#xD;
       18. Fischer KG. Essentials of anticoagulation in hemodialysis.Hemodial Int. 2007;11:178-189.&#xD;
&#xD;
       19. Kaye M, Vasilevsky M, Ketis M. The effect on blood pressure of an acute fall in ionized&#xD;
           calcium during hemodialysis. A randomized study in two patients. Clin Nephrol.&#xD;
           1998;50:361-366.&#xD;
&#xD;
       20. Van der Sande FM, Cheriex EC, Van Kuijk WHM, Leunissen KML. Effect of dialysate calcium&#xD;
           concentrations on intradialytic blood pressure course in cardiac-compromised patients.&#xD;
           Am J Kidney Dis. 1998;32:125-131.&#xD;
&#xD;
       21. Leunissen KML, Van den Berg BW, van Hooff JP. Ionized calcium plays a pivotal role in&#xD;
           controlling blood pressure during haemodialysis. Blood Purif. 1989;7:233-239.&#xD;
&#xD;
       22. Sherman RA, Bialy GB, Gazinski B, Bernholc AS, Eisinger RP. The effect of dialysate&#xD;
           calcium levels on blood pressure during hemodialysis. Am J Kidney Dis. 1986;8:244-247.&#xD;
&#xD;
       23. Maynard JC, Cruz C, Kleerekoper M, Levin NW. Blood pressure response to changes in serum&#xD;
           ionized calcium during hemodialysis. Ann Intern Med. 1986;104:358-361.&#xD;
&#xD;
       24. Gabutti L, Ross V, Duchini F, Mombelli G, Marone C. Does Bicarbonate transfer have&#xD;
           relevant hemodynamic consequences in standard hemodialysis? Blood Purif.&#xD;
           2005;23:365-372.&#xD;
&#xD;
       25. Gabutti L, Ferrari N, Giudici G, Mombelli G, Marone C. Unexpected haemodynamic&#xD;
           instability associated with standard bicarbonate haemodialysis. Nephrol Dial Transplant.&#xD;
           2003;18:2369-2376.&#xD;
&#xD;
       26. Nossel HL, Yudelman I, Canfield RE, Butler VP, Spanondis K, Wilner GD, Qureshi GD.&#xD;
           Measurement of fibrinopeptide A in human blood. J Clin Invest. 1974;54:43-53.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Consequences on systemic haemodynamics</measure>
    <time_frame>Study duration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Consequences on coagulation, acid-base status, calcium balance and dialysis efficiency</measure>
    <time_frame>Study duration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Haemodialysis</condition>
  <arm_group>
    <arm_group_label>Citrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Citrate dialysate for haemodialysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acetate dialysate</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Citrate dialysate</intervention_name>
    <description>dialysis fluid composition for Citrate (C) and Acetate (A): acetate [3.0 mmol/L in A and 0.3 in C], citrate [0 mmol/L in A and 0.8 in C]</description>
    <arm_group_label>Citrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Acetate dialysate</intervention_name>
    <description>dialysis fluid composition for Citrate (C) and Acetate (A): acetate [3.0 mmol/L in A and 0.3 in C], citrate [0 mmol/L in A and 0.8 in C]</description>
    <arm_group_label>Acetate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  chronic haemodialysis patients&#xD;
&#xD;
          -  dialysed 3 to 4 hours three times a week, who were&#xD;
&#xD;
          -  clinically stable and without intercurrent illnesses&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  intercurrent illnesses&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luca Gabutti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Regionale di Locarno</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedale Regionale di Locarno</name>
      <address>
        <city>Locarno</city>
        <state>Ticino</state>
        <zip>6600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <study_first_submitted>July 16, 2008</study_first_submitted>
  <study_first_submitted_qc>July 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2008</study_first_posted>
  <last_update_submitted>July 17, 2008</last_update_submitted>
  <last_update_submitted_qc>July 17, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2008</last_update_posted>
  <responsible_party>
    <name_title>Luca Gabutti; Head of Department</name_title>
    <organization>Ospedale Regionale di Locarno</organization>
  </responsible_party>
  <keyword>Citric acid</keyword>
  <keyword>citrate</keyword>
  <keyword>acetic acid</keyword>
  <keyword>acetate</keyword>
  <keyword>haemodialysis</keyword>
  <keyword>calcium</keyword>
  <keyword>hypotension</keyword>
  <keyword>haemodynamics</keyword>
  <keyword>Dialysate for Haemodialysis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dialysis Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

